Trials / Completed
CompletedNCT02143999
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 403 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Conditions
Timeline
- Start date
- 2014-06-27
- Primary completion
- 2016-12-30
- Completion
- 2016-12-30
- First posted
- 2014-05-21
- Last updated
- 2017-06-27
Locations
24 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02143999. Inclusion in this directory is not an endorsement.